Featuring experts from Mass General Hospital and the Cannabis Chamber of Commerce, among other institutions
The following is from the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, which with support from the Oswald DeN. Cammann Fund at Harvard University and the Gracias Family Foundation is hosting this virtual event:
In late 2025, President Trump signed an Executive Order to expedite the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act.
If finalized, the reclassification would mark a significant policy shift with concrete legal, economic, and research implications. What does this mean for recreational/medical use, state and federal drug law, and cannabis research?
Our panel of experts bring multidisciplinary perspectives to this complicated issue.
The panel features Mason Marks, a professor at Florida State University College of Law and senior fellow at the Petrie-Flom Center; Dr. Peter Grinspoon, a primary care physician at Massachusetts General Hospital and instructor at Harvard Medical School; Ifetayo Harvey, executive director of the People of Color Psychedelic Collective and affiliated researcher at the Petrie-Flom Center; Hirsh Jain, CEO of Ananda Strategy and vice chair of the Cannabis Chamber of Commerce; and Robert Mikos, a professor at Vanderbilt Law School and affiliated researcher at the Petrie-Flom Center.
